Infinity Pharmaceuticals Inc Q1 2018 Institutional Investor Sentiment Better Than Expected

June 11, 2018 - By Migdalia James

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Logo

Sentiment for Infinity Pharmaceuticals Inc (NASDAQ:INFI)

Infinity Pharmaceuticals Inc (NASDAQ:INFI) institutional sentiment increased to 1.32 in 2018 Q1. Its up 0.70, from 0.62 in 2017Q4. The ratio has increased, as 25 active investment managers increased or opened new positions, while 19 sold and trimmed equity positions in Infinity Pharmaceuticals Inc. The active investment managers in our partner’s database reported: 27.14 million shares, up from 24.33 million shares in 2017Q4. Also, the number of active investment managers holding Infinity Pharmaceuticals Inc in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 7 Reduced: 12 Increased: 16 New Position: 9.

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. The company has market cap of $107.09 million. The Company’s lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma is in Phase 1 clinical study. It currently has negative earnings. The firm has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib.

The stock increased 1.60% or $0.03 during the last trading session, reaching $1.91. About 117,436 shares traded. Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has risen 16.67% since June 11, 2017 and is uptrending. It has outperformed by 4.10% the S&P500.

Analysts await Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) to report earnings on August, 2. They expect $-0.20 earnings per share, up 41.18 % or $0.14 from last year’s $-0.34 per share. After $-0.18 actual earnings per share reported by Infinity Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 11.11 % negative EPS growth.

Bvf Inc Il holds 2.08% of its portfolio in Infinity Pharmaceuticals, Inc. for 9.77 million shares. Ghost Tree Capital Llc owns 1.75 million shares or 0.74% of their US portfolio. Moreover, Platinum Investment Management Ltd has 0.08% invested in the company for 1.30 million shares. The New York-based Clear Harbor Asset Management Llc has invested 0.03% in the stock. Gsa Capital Partners Llp, a United Kingdom-based fund reported 302,154 shares.

Since January 1, 0001, it had 1 insider purchase, and 1 sale for $2.96 million activity.

Another recent and important Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) news was published by Streetinsider.com which published an article titled: “Infinity Pharma (INFI) Announces IPI-549 Clinical and Translational Data from Ongoing Phase 1/1b Study” on June 04, 2018.

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.